Advances in Metabolic Imaging in Patients with Elevated Prostate Specific Antigen (PSA)

EAU-EBU Update Series

Volumn 4, Issue 1, 2006, Pages 20-32

  Seitz, Michael ^a   Scher, Bernhard ^a   Graser, Anno ^a   Reich, Oliver ^a   Gratzke, Christian ^a   Scherr, Michael ^a   Stief, Christian G ^a   Mueller Lisse, Ullrich G ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Imaging; MRI; PET; Prostate cancer

Indexed keywords

ACETIC ACID; ANTIANDROGEN; CARBON 11; CHOLINE; FLUORODEOXYGLUCOSE F 18; GONADORELIN AGONIST; MEDRONATE TECHNETIUM TC 99M; PROSTATE SPECIFIC ANTIGEN;

ANTIGEN DETECTION; ARTICLE; BONE SCINTISCANNING; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; DIAGNOSTIC IMAGING; HUMAN; MEDICAL LITERATURE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; POSITRON EMISSION TOMOGRAPHY; PROSTATE CANCER; PROSTATECTOMY; SENSITIVITY AND SPECIFICITY;

EID: 33745502828     PISSN: 18712592     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eeus.2005.11.001     Document Type: Article

References (67)

1. Scardino P.T. Early detection of prostate cancer. Urol Clin N Am 16 (1989) 635-655
2. Cornud F., Belin X., Piron D., Chretien Y., Flam T., Casanova J.M., et al. Color Doppler-guided prostate biopsies in 591 patients with an elevated serum PSA level: impact on Gleason score for nonpalpable lesions. Urology 49 5 (1997 May) 709-715
3. Halpern E.J., Verkh L., Forsberg F., Gomella L.G., Mattrey R.F., and Goldberg B.B. Initial experience with contrast-enhanced sonography of the prostate. AJR Am J Roentgenol 174 6 (2000 Jun) 1575-1580
4. Wijkstra H., Wink M.H., and de la Rosette J.J. Contrast specific imaging in the detection and localization of prostate cancer. World J Urol 22 5 (2004 Nov) 346-350
5. Heuck A., Scheidler J., Sommer B., Graser A., Muller-Lisse U.G., and Massmann J. MR imaging of prostate cancer. Radiologe 43 6 (2003 Jun) 464-473
6. Wilkinson B.A., and Hamdy F.C. State-of-the-art staging in prostate cancer. BJU Int 87 5 (2001 Mar) 423-430
7. Smith Jr. J.A., Scardino P.T., Resnick M.I., Hernandez A.D., Rose S.C., and Egger M.J. Transrectal ultrasound versus digital rectal examination for the staging of carcinoma of the prostate: results of a prospective, multi-institutional trial. J Urol 157 3 (1997 Mar) 902-906
8. Liebross R.H., Pollack A., Lankford S.P., Zagars G.K., von Eschenbach A.C., and Geara F.B. Transrectal ultrasound for staging prostate carcinoma prior to radiation therapy: an evaluation based on disease outcome. Cancer 85 7 (1999 Apr 1) 1577-1585
9. Okada J., Yoshikawa K., Itami M., Imaseki K., Uno K., Itami J., et al. Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma: a comparison with proliferative activity. J Nucl Med 33 3 (1992 Mar) 325-329
10. Inaba T. Quantitative measurements of prostatic blood flow and blood volume by positron emission tomography. J Urol 148 5 (1992 Nov) 1457-1460
11. Oyama N., Akino H., Suzuki Y., Kanamaru H., Sadato N., Yonekura Y., et al. The increased accumulation of [18F]fluorodeoxyglucose in untreated prostate cancer. Jpn J Clin Oncol 29 12 (1999 Dec) 623-629
12. Heicappell R., Muller-Mattheis V., Reinhardt M., Vosberg H., Gerharz C.D., Muller-Gartner H., et al. Staging of pelvic lymph nodes in neoplasms of the bladder and prostate by positron emission tomography with 2-[(18)F]-2-deoxy-D-glucose. Eur Urol 36 6 (1999 Dec) 582-587
13. Seltzer M.A., Barbaric Z., Belldegrun A., Naitoh J., Dorey F., Phelps M.E., et al. Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer. J Urol 162 4 (1999 Oct) 1322-1328
14. Hara T., Kosaka N., and Kishi H. PET imaging of prostate cancer using carbon-11-choline. J Nucl Med 39 6 (1998 Jun) 990-995
15. Oyama N., Akino H., Kanamaru H., Suzuki Y., Muramoto S., Yonekura Y., et al. 11C-acetate PET imaging of prostate cancer. J Nucl Med 43 2 (2002 Feb) 181-186
16. Shreve P., Chiao P.C., Humes H.D., Schwaiger M., and Gross M.D. Carbon-11-acetate PET imaging in renal disease. J Nucl Med 36 (1995) 1595-1601
17. Shreve P.D., and Gross M.D. Imaging of the pancreas and related diseases with PET carbon-11-acetate. J Nucl Med 38 (1997) 1305-1310
18. Yoshimoto M., Waki A., Yonekura Y., et al. Characterization of acetate metabolism in tumor cells in relation to cell proliferation: acetate metabolism in tumor cells. Nucl Med Biol 28 (2001) 117-122
19. Liu R.S. Clinical application of (C-11)acetate in oncology [abstract]. Clin Positron Imaging 3 (2000) 185
20. Oyama N., Miller T.R., Dehdashti F., Siegel B.A., Fischer K.C., Michalski J.M., et al. 11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse. J Nucl Med 44 (2003) 549-555
21. Hara T., Kosaka N., Shinoura N., and Kondo T. PET imaging of brain tumor with [methyl-11C]choline. J Nucl Med 38 (1997) 842-847
22. Kotzerke J., Volkmer B.G., Glatting G., van den Hoff J., Gschwend J.E., Messer P., et al. Intraindividual comparison of [11C]acetate and [11C]choline PET for detection of metastases of prostate cancer. Nuklearmedizin 42 1 (2003 Feb) 25-30
23. Coleman R., DeGrado T., Wang S., Baldwin S., Orr M., Reiman R., et al. Preliminary evaluation of F-18 Fluorocholine (FCH) as a PET tumor imaging agent. Clin Positron Imaging 3 4 (2000 Jul) 147
24. DeGrado T.R., Coleman R.E., Wang S., Baldwin S.W., Orr M.D., Robertson C.N., et al. Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. Cancer Res 61 1 (2001 Jan 1) 110-117
25. Hara T., Kosaka N., and Kishi H. Development of (18)F-fluoroethylcholine for cancer imaging with PET: synthesis, biochemistry, and prostate cancer imaging. J Nucl Med 43 2 (2002 Feb) 187-199
26. Yoshida S., Nakagomi K., Goto S., Futatsubashi M., and Torizuka T. 11 C-Choline positron emission tomography in prostate cancer: primary staging and recurrent site staging. Urol Int 74 (2005) 214-220
27. DeJong I.J., Pruim J., Elsinga P.H., Vaalburg W., and Mensink H.J.A. Visualization of prostate cancer with 11C-choline positron emission tomography. Eur Urol 42 (2002) 18-23
28. De Jong I.J., Prium J., Elsinga P.H., Vaalburg W., and Mensink H.J.A. Preoperative staging of pelvic lymph nodes in prostate cancer by 11C-Choline PET. J Nucl Med 44 (2003) 331-335
29. Kotzerke J., Volkmer B.G., Neumaier B., Gschwend J.E., Hautmann R.E., and Reske S.N. Carbon-11 acetate positron emission tomography can detect local recurrence of prostate cancer. Eur J Nucl Med Mol Imaging 29 10 (2002 Oct) 1380-1384
30. Fricke E., Machtens S., Hofmann M., van den Hoff J., Bergh S., Brunkhorst T., et al. Positron emission tomography with 11C-acetate and 18F-FDG inprostate cancer patients. Eur J Nucl Med Mol Imaging 30 4 (2003 Apr) 607-611
31. De Jong I.J., Pruim J., Elsinga P.H., Vaalburg W., and Mensink H.J.A. 11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer. Eur Urol 44 (2003) 32-38
32. Picchio M., Messa C., Landoni C., Gianolli L., Sironi S., Nrioschi M., et al. Value of 11C-choline-positron emission tomography for re-staging prostate cancer: a comparison with 18F-fluorodeoxyglucose-positron emission tomography. J Urol 169 4 (2003 Apr) 1337-1340
33. Amsellem-Ouazana D., Younes P., Conquy S., Peyromaure M., Flam T., Debre B., et al. Negative prostatic biopsies in patients with a high risk of prostate cancer. Is the combination of endorectal MRI and magnetic resonance spectroscopy imaging (MRSI) a useful tool? A preliminary study. Eur Urol 47 5 (2005 May) 582-586
34. McNeal J.E. Regional morphology and pathology of the prostate. Am J Clin Pathol 49 (1968) 347-357
35. McNeal J.E. Normal histology of the prostate. Am J Surg Pathol 12 (1988) 619-633
36. Hricak H., Dooms G.C., McNeal J.E., et al. MR imaging of the prostate gland: normal anatomy. Am J Roentgenol 148 (1987) 51-58
37. Mueller-Lisse U.G., Heuck A.F., Schneede P., et al. Postoperative MRI in patients undergoing interstitial laser coagulation thermotherapy of benign prostatic hyperplasia. J Comput Assist Tomogr 20 (1996) 273-278
38. Mueller-Lisse U., Mueller-Lisse U., Scheidler J., Klein G., and Reiser M. Reproducibility of image interpretation in MRI of the prostate: application of the sextant framework by two different radiologists. Eur Radiol 15 (2005) 1826-1833
39. Coakley F.V., Qayyum A., and Kurhanewicz J. Magnetic resonance imaging and spectroscopic imaging of prostate cancer. J Urol 170 (2003) 69-76
40. Engelbrecht M.R., Jager G.J., Laheij R.J., Verbeek A.L., van Lier H.J., and Barentsz J.O. Local staging of prostate cancer using magnetic resonance imaging: a meta-analysis. Eur Radiol 12 9 (2002) 2294-2302
41. Kiessling F., Lichy M., Grobholz R., Farhan N., Heilmann M., Michel M.S., et al. Detektion von Prostatakarzinome mit T1-gewichteter Kontrastmittel-unterstützter dynamischer MRT. Wertigkeit des Zweikompartimentenmodells. Radiologe 43 (2003) 474-480
42. Schlemmer H.P., Merkle J., Grobholz R., Jaeger T., Michel M.S., Werner A., et al. Can pre-operative contrast-enhanced dynamic MR imaging for prostate cancer predict microvessel density in prostatectomy specimens?. Eur Radiol 14 (2004) 309-317
43. Costello L.C., and Franklin R.B. Concepts of citrate production and secretion by prostate: 1. Metabolic relationships. Prostate 18 (1991) 25-46
44. Costello L.C., and Franklin R.B. Concepts of citrate production and secretion by prostate: 2. Hormonal relationships in normal and neoplastic prostate. Prostate 19 (1991) 181-205
45. Kurhanewicz J., Vigneron D.B., Nelson S.J., Hricak H., MacDonald J.M., Konety B., et al. Citrate as an in vivo marker to discriminate prostate cancer from benign prostatic hyperplasia and normal prostate peripheral zone: detection via localized proton spectroscopy. Urology 45 (1995) 459-466
46. Costello L.C., Franklin R.B., and Narayan P. Citrate in the diagnosis of prostate cancer. Prostate 38 (1999) 237-245
47. Mueller-Lisse U.G., and Scherr M. 1H-MR-Spektroskopie der Prostata: Ein Überblick. Radiologe 43 (2003) 481-488
48. 3) spatial resolution. Radiology 198 3 (1996 Mar) 795-805
49. Scheidler J., Hricak H., Vigneron D.B., Yu K.K., Sokolov D.L., Huang R.L., et al. Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging - clinicopathologic study. Radiology 213 (1999) 473-480
50. Mueller-Lisse U.G., Vigneron D.B., Hricak H., Swanson M.G., Carroll P.R., Bessette A., et al. Localized prostate cancer: effect of hormone deprivation therapy measured by using combined three-dimensional 1H MR spectroscopy and MR imaging: clinicopathologic case-controlled study. Radiology 221 (2001) 380-390
51. Mueller-Lisse U.G., Swanson M.G., Vigneron D.B., Hricak H., Bessette A., Males R.G., et al. Time-dependent effects of hormone-deprivation therapy on prostate metabolism as detected by combined magnetic resonance imaging and 3D magnetic resonance spectroscopic imaging. Magn Reson Med 46 (2001) 49-57
52. Yu K.K., Scheidler J., Hricak H., Vigneron D.B., Zaloudek C.J., Males R.G., et al. Prostate cancer: prediction of extracapsular extension with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging. Radiology 213 (1999) 481-488
53. Wang L., Mullerad M., Chen H.N., Eberhardt S.C., Kattan M.W., Scardino P.T., et al. Prostate cancer: incremental value of endorectal MR imaging findings for prediction of extracapsular extension. Radiology 232 (2004) 133-139
54. Mullerad M., Hricak H., Wang L., Chen H.N., Kattan M.W., and Scardino P.T. Prostate cancer: detection of extracapsular extension by genitourinary and general body radiologists at MR imaging. Radiology 232 (2004) 140-146
55. Maßmann J., Funk A., Altwein J., and Praetorius M. Prostatakarzinom (PC) - eine organspezifische Neoplasie aus Sicht der Pathologie. Radiologe 43 (2003) 423-431
56. Beyersdorff D., Taupitz M., Winkelmann B., et al. Patients with a history of elevated prostate-specific antigen levels and negative transrectal US-guided quadrant or sextant biopsy results: value of MR imaging. Radiology 702 (2002) 701-706
57. Yuen J.S., Thng C.H., Tan P.H., Khin L.W., Phee S.J., Xiao D., et al. Endorectal magnetic resonance imaging and spectroscopy for the detection of tumor foci in men with prior negative transrectal ultrasound prostate biopsy. J Urol 171 (2004) 1482-1486
58. Menard C., Smith I.C.P., Somorjai R.L., Leboldus L., Patel R., Littman C., et al. Magnetic resonance spectroscopy of the malignant prostate gland after radiotherapy: a histopathologicstudy of diagnostic validity. Int J Radiat Oncol Biol Phys 50 (2001) 317-323
59. DiBiase S.J., Hosseinzadeh K., Gullapalli R.P., Jacobs S.C., Naslund M.J., Sklar G.N., et al. Magnetic resonance spectroscopic imaging-guided brachytherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 52 (2002) 429-438
60. Coakley F.V., Teh H.S., Qayyum A., Swanson M.G., Lu Y., Roach III M., et al. Endorectal MR imaging and MR spectroscopic imaging for locally recurrent prostate cancer after external beam radiation therapy: preliminary experience. Radiology 233 (2004) 441-448
61. Huisman H.J., Futterer J.J., van Lin E.N., Welmers A., Scheenen T.W., van Dalen J.A., et al. Prostate cancer: precision of integrating functional MR imaging with radiation therapy treatment by using fiducial gold markers. Radiology 236 1 (2005 Jul) 311-317
62. Kurhanewicz J., Vigneron D.B., Hricak H., Parivar F., Nelson S.J., Shinohara K., et al. Prostate cancer: metabolic response to cryosurgery as detected with 3D H-1 MR spectroscopic imaging. Radiology 200 (1996) 489-496
63. Parivar F., Hricak H., Shinohara K., Kurhanewicz J., Vigneron D.B., Nelson S.J., et al. Detection of locally recurrent prostate cancer after cryosurgery: evaluation by transrectal ultrasound, magnetic resonance imaging, and three-dimensional proton magnetic resonance spectroscopy. Urology 48 (1996) 594-599
64. Kaji Y., Kurhanewicz J., Hricak H., Sokolov D.L., Huang L.R., Nelson S.J., et al. Localizing prostate cancer in the presence of postbiopsy changes on MR imaging: role of proton MR spectroscopic imaging. Radiology 206 (1998) 785-790
65. Qayyum A., Coakley F.V., Lu Y., Olpin J.D., Wu L., Yeh B.M., et al. Organ-confined prostate cancer: effect of prior transrectal biopsy on endorectal MRI and MR spectroscopic imaging. AJR Am J Roentgenol 183 (2004) 1079-1083
66. Heerschap A., Jager G.J., van der Graaf M., Barentsz J.O., and Ruijs S.H. Proton MR spectroscopy of the normal human prostate with an endorectal coil and a double spin-echo pulse sequence. Magn Reson Med 37 (1997) 204-213
67. Liney G.P., Turnbull L.W., Lowry M., Turnbull L.S., Knowles A.J., and Horsman A. In vivo quantification of citrate concentration and water T2 relaxation time of the pathologic prostate gland using 1H MRS and MRI. Magn Reson Imaging 15 (1997) 1177-1187